Printer Friendly

ESCAGENETICS NAMES DR. THOMAS M. GLENN PRESIDENT AND CHIEF OPERATING OFFICER OF ITS PHYTOPHARMACEUTICALS SUBSIDIARY

 SAN CARLOS, Calif., April 1 /PRNewswire/ -- ESCAgenetics Corp.'s (AMEX: ESN) subsidiary, PHYTOpharmaceuticals Inc., today announced the appointment of Thomas M. Glenn, Ph.D., to the new position of president and chief operating officer. Glenn will oversee overall execution of the company's botanical-based drug discovery and commercial development programs. Glenn's recent background includes serving as vice president of pharmaceutical development at Cytel Corp. and president of BioCryst Inc. He was vice president of pharmacological sciences at Genentech Inc. and, prior to that, he served as senior vice president and director of research of Ciba-Geigy Corp.
 "Dr. Glenn is a seasoned pharmaceutical executive with an impressive R&D and business management track record, and we are fortunate to have him to lead our phytopharmaceuticals efforts for the next generation of pharmaceutical products," said Douglas MacMaster Jr., chairman and chief executive officer of PHYTOpharmaceuticals Inc.
 PHYTOpharmaceuticals is committed to botanical-based drug discovery through a comprehensive plant-sourcing and pharmacological screening program. PHYTOpharmaceuticals' approach to drug discovery includes plant collection and certified extract production laboratories in Asia and Latin America. The company's related capabilities also include proprietary plant cell tissue culture and chemical genetics programs for lead compound modification and discovery, plant chemistry, plant cell bioreactor production of pharmaceutical compounds, as well as agricultural operations suitable for large-scale production of plant- derived pharmaceutical compounds. "Under the leadership of Dr. Glenn, an accomplished pharmaceutical executive, we are putting together a one-of-a-kind, plant-drug pharmacological screening and drug discovery team," said Dr. Raymond J. Moshy, ESCAgenetics' chief executive officer.
 The parent company, ESCAgenetics Corp., has been successful in plant cell tissue culture production of taxol in bioreactors. Taxol will be produced in a pilot plant/commercial scale-up facility during 1993, and the company expects to supply taxol to the pharmaceutical industry in 1994. In addition, PHYTOpharmaceuticals has discovered novel taxanes as part of its plant cell tissue culture drug discovery program.
 PHYTOpharmaceuticals Inc., a subsidiary of ESCAgenetics Corp., specializes in the discovery and development of plant-derived pharmaceuticals using its global pharmaceutical-based agricultural network and proprietary plant cell tissue culture technology.
 -0- 4/1/93
 /CONTACT: Dr. Raymond J. Moshy, president and chief executive officer of ESCAgenetics, 415-595-5335/
 (ESN)


CO: ESCAgenetics Corp.; PHYTOpharmaceuticals Inc. ST: California IN: MTC SU: PER

LH-TM -- SF004 -- 1852 04/01/93 08:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1993
Words:381
Previous Article:THE SOFTWARE TOOLWORKS APPOINTS JAMES P. MASLYN AS CHIEF FINANCIAL OFFICER
Next Article:PROTEIN DESIGN LABS APPOINTS JAMES CORNETT DIRECTOR, BUSINESS DEVELOPMENT
Topics:


Related Articles
DR. WILLIAM SHARP APPOINTED DEAN OF RESEARCH AT RUTGERS' COOK COLLEGE AND NAMED MEMBER OF PHYTO'S SCIENTIFIC ADVISORY BOARD
ESCAGENETICS' PHYTOPHARMACEUTICALS INC. NAMES SCIENTIFIC ADVISORY BOARD; DR. MEINHART ZENK NAMED CHAIRMAN
ESCAGENETICS' PHYTOPHARMACEUTICALS INC. NAMES SCIENTIFIC ADVISORY BOARD; DR. MEINHART ZENK NAMED CHAIRMAN
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
PHYTOPHARMACEUTICALS AND ENZON JOIN FORCES TO ENHANCE TAXOL'S POTENTIAL
PHYTOPHARMACEUTICALS INC. AND MACRONEX INC. SIGN COLLABORATIVE RESEARCH AGREEMENT
PHYTOPHARMACEUTICALS INC. NAMES WILLIAM A. HASLER TO BOARD OF DIRECTORS
ESCAGENETICS RECEIVES SBIR AWARD TO DISCOVER NOVEL TAXOIDS
ESCAGENETICS' SUBSIDIARY PHYTOPHARMACEUTICALS RECEIVES $1.8 MILLION FROM SUN HILL GLUCOSE CO., LTD. OF KOREA IN PAYMENT FOR STOCK PURCHASED UNDER...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters